

Program of the 13rd conference of the International Society for the Study of Drug Policy, Paris, France

Day 1: Wednesday, May 22nd					
8:00 to 9:00 AM	Registration				
9:00 to 9:20 AM	<p align="center">Opening and welcome Marie Jauffret-Roustide, Paris Conference Host Alex Stevens, President of the ISSDP Anne Souyris, Paris Deputy Major in charge of health issues</p>				
9:20 to 10:20 AM	<p align="center">First plenary session: “The ontological politics of drug policy: a critical realist approach” Keynote presentation by Alex Stevens, Professor in Criminal Justice, University of Kent in conversation with Kari Lancaster, Senior Research Fellow at UNSW and Rosalie Liccardo Pacula, Co-Director of the RAND Drug Policy Research Center Chair: Alison Ritter</p>				
10:20 to 10:50 AM	Break				
10:50 to 12:20 PM	Exploring changes in the US 'heroin' risk environment: HIV, drug supply, polysubstance use and overdose	The roles of measures and perceptions in Cannabis regulation	Cryptomarkets: supply, demand, and hidden spaces of transaction	New models for public health treatment funding and enforcement	Age, gender, family and perception factors in access to drug treatment and services
Room	Auditorium	R2-01	R1-13	R1-14	R1-15
Chair	Dan Ciccarone	Beau Kilmer	Gary Potter	Andrew McAuley	Karine Bertrand
	<u>Dan Ciccarone</u> Missed opportunities: viral transmission risks among a new cohort of injectors in the United States “heroin” epidemic	<u>Yuyan Shi & D. Liang</u> The associations between recreational cannabis commercialization and cannabis exposures reported to the US National Poison	<u>Michala Kowalski,</u> J. Aldridge, R. Coomber, J. Martin & M.J. Barratt Cryptomarkets, ignorance and harm: does drug expertise matter more in a	<u>Osasuyi Dirisu & A. Klein</u> Non-medical use of tramadol in West Africa: The tensions between law enforcement, illegal supply pathways and	Mélanie Quétier, M. Bouchon, N.N. Lwin & S.N. Pan Sociocultural and religious norms and values at the foundation of repression and

		Data System, 2010-2017	high drug availability setting?	public health.	violence towards people who use drugs in Kachin State, Myanmar
	<p><u>Dan Rosenblum</u></p> <p>The rapidly changing US illicit opioid market and the potential for an improved early warning system: evidence from Ohio drug crime labs</p>	<p><u>David-Martin Milot & M. Jauffret-Roustide</u></p> <p>Psychoactive substances and their regulatory systems: how social representations influence policies in France</p>	<p><u>Shann Hulme, C.E. Hughes & S. Nielsen</u></p> <p>The price of drugs supplied on the pharmaceutical black market: an Australian case study</p>	<p><u>Chris Wilkins & M. Rychert</u></p> <p>The risks of cannabis industry funding of community and drug treatment services – Insights from gambling</p>	<p><u>Meredith Meacham, K. Lynch, P. Coffin & E. Riley</u></p> <p>An examination of fentanyl metabolites in a primarily crack cocaine-using population of unstably housed women in San Francisco, USA</p>
	<p><u>Georgiy Bobashev</u></p> <p>Polydrug use patterns among prescription opioid misusers and heroin users. Results from the National Household Survey of Drug Use and Health</p>	<p><u>Lindsey Beltz, C. Mosher & J. Schwartz</u></p> <p>Assessing perceived effects of 1-502: A survey on recreational cannabis in Washington State</p>	<p><u>Patrick Shortis</u></p> <p>Towards an understanding of resilience in cryptomarkets</p>	<p><u>Jorge Mantilla</u></p> <p>Supply resilience and therapeutic policing: the new face of war on drugs in Colombia</p>	<p><u>Maria Caiata-Zufferey, M. Luciani, P. di Giulio, L. Pezzoli, C. Prandi & A. Moriggia</u></p> <p>The aging process of people who use drugs in opioid substitution treatment: design and preliminary results of an interdisciplinary and participatory research project in Southern Switzerland</p>
	<p><u>Jay Unick</u></p> <p>Divergence in deaths vs. hospitalizations for heroin and other opiate overdoses. Changes in risk or problems of classification?</p>	<p><u>Clayton Mosher</u></p> <p>Youth use of marijuana in Washington State - Trends and correlates</p>	<p><u>Nicolae Craciunescu</u></p> <p>Drugs in the context of consumer culture: the sign-value of the products sold on the Darknet marketplaces</p>	<p><u>Aysel Sultan</u></p> <p>The stake of a non-standard comparative approach: Treatment policies of Azerbaijan and Germany</p>	<p><u>Sarah A. Daniels, T.A. Sanchez, M. St. Pierre & Z. Walsh</u></p> <p>Maternal cannabis use: Examining the relationships between cannabis use, attachment, and parenting outcomes in Canadian mothers</p>

12:20 PM to 1:30 PM	Lunch break				
12:20 PM to 1:30 PM	Poster presentations				
1:30 PM to 3 PM	National and cultural contexts: comparative drug policy analysis	Policy controversies about harm reduction	Cannabis: consumer experiences and evolving perceptions	Legalizing, implementing, and assessing substitution treatment	Measuring, treating, and prohibiting drug use among marginalized and migrating drug users
Room	Auditorium	R2-01	R1-13	R-14	R1-15
Chair	Scott Burris	Naomi Burke-Shyne	David-Martin Milot	Polly Radcliffe	Anne Line Bretteville-Jensen
	<u>Siobhan Callaghan</u> Issues in comparing national drug policies: Utilising typologies to identify drug policy regimes and explore cultural contexts	<u>Tuukka Tammi</u> Political process on launching drug consumption rooms in Helsinki	<u>Ashely Granville, J. Chopin, P. Esseiva, R. Udrisard, F. Zobel, & M. Jendly</u> Lights on small-scale cannabis growers: Findings from a European web survey and face to face interviews	<u>Sarah Heins & R. Castillo</u> Evaluation of the impact of morphine equivalent daily dose policies on high dose opioid prescribing	<u>Louise Christensen, B. Bjerge & E. Houborg</u> Agents of care and control within the welfare State: The interrelation between drug policies, social policies and services towards people who experience social marginalization
	<u>Kim Moeller</u> Sisters are never alike? – Drug control intensity in the Nordic countries	<u>Marie Jauffret-Roustide & I. Cailbault</u> Controversy over drug consumption rooms: from assessing social acceptability to sharing urban spaces	<u>Daniel Bear</u> Young people's decision making about cannabis	<u>Atul Ambekar, R. Rao, A. Agrawal, S. Singh & M. Varshney</u> Ambiguities in the legal frameworks for treatment of drug use disorders versus other mental health conditions: Reflections from the recently enacted mental	<u>Charlotte De Kock</u> Monitoring migration-related indicators in European drug treatment: Identifying pitfalls and challenges in registration, data collection and database coupling methods

				healthcare law in India	
	<p><u>Clara Musto</u> Advocacy coalitions moral foundations: developing cross-cultural variations in drug policy change explanations</p>	<p><u>Esben Houborg, M. Bancroft & J. Wielandt Holt</u> The impact of a local drug policy on drug users' everyday life on an open drug scene</p>	<p><u>Sharon R. Sznitman, Y. Ben Baruch, T. Greene & M. Gelkopf</u> The association between physical pain and cannabis use in daily life: An experience sampling method</p>	<p><u>Pedro Mateu-Gelabert, H. Guarino & S. Campos</u> Atención VIH (A!VIH): An integrated Seek, Test, Treat and Retain (STTR) - Medication-Assisted Treatment (MAT) intervention for PWID in Latin America.</p>	<p><u>Sarah Tosh</u> Drug prohibition and the criminalization of immigrants: The compounding of drug war disparities in the modern United States deportation regime</p>
	<p>R. Kert, A. Lehner, <u>Brendan Hughes</u> & O. Dalbinoë Comparing drug trafficking penalties across the EU</p>	<p><u>Tara Marie Watson, L. Barnaby, A. M. Bayoumi, L. Challacombe, A. Wright & C. Strike</u> “This is a health service. Leave it alone”: Staff and client views on policing boundaries involving supervised consumption services</p>	<p><u>Sebastian Aguiar</u> What do people think afterwards? Characterizing public opinion on cannabis regulation in Uruguay through open-ended responses</p>	<p><u>Samara Mayer, A. Fowler, J. Boyd & R. McNeil</u> Understanding motivations for the initiation of injectable opioid agonist treatment: An ethnographic study of patient care experiences in Vancouver, Canada</p>	<p><u>S. MacGregor & Aileen O’Gorman</u> Social policy paradigms: framing perceptions and policies towards people who are poor and use drugs.</p>
3 PM to 3:30 PM	Break				
3:30 PM to 5:00 PM	Illicit drugs and the transformation of war economies	Opioid use and responses - Opioid crisis	Methods in measurements and assessments of largescale drug policy	Polyuse and issues in specific injecting communities	Medical cannabis: use and regulations
Room	Auditorium	R2-01	R1-13	R1-14	R1-15
Chair	John Collins	Peter Reuter	Brandon Hughes	Fay Dennis	Sharon Sznitzman

	<p><u>John Collins</u></p> <p>Theorising fragmentation and change in global drug control</p>	<p><u>Bryce Pardo</u></p> <p>Why fentanyl in North America? Why now?</p>	<p><u>Ayden Scheim</u>, N. Maghsoudi, S. Churchill, Z. Marshall & D. Werb</p> <p>What matters and what has been measured? A systematic review of research on the impacts of implementing drug decriminalization or regulation</p>	<p><u>Jennifer Havens & H. Knudsen</u></p> <p>Recent transition to methamphetamine use among nonmedical prescription opioid users from Appalachian Kentucky, 2008-2019</p>	<p><u>Bernd Werse, L. Klaus & G. Kamphausen</u></p> <p>Hybrid users – results from a qualitative study on the blurred boundaries between recreational and medical cannabis use</p>
	<p><u>Jasmine Bhatia</u></p> <p>Unsettling the peace? The role of illicit economies in peace processes</p>	<p><u>Jirka Taylor & P. Reuter</u></p> <p>International experiences with fentanyl</p>	<p><u>Hannah Knudsen & J. Havens</u></p> <p>Using conjoint analysis to study health policy changes: an example from a cohort of persons who use drugs</p>	<p><u>Katherine McLean, K. Rigg, S. Monnat, A. Verdery & G. Sterner</u></p> <p>“Pushed in the same way”: Exploring the role of cocaine in heroin initiation, continuation, and desistance</p>	<p><u>Frédérique Bawin</u></p> <p>Accessing illicit medicines. The search for medicinal cannabis in Flanders</p>
	<p><u>Jonathan Goodhand</u></p> <p>Re-imagining the narco frontier</p>	<p><u>Rosanna Smart & B. Kilmer</u></p> <p>Can heroin-assisted treatment help reduce fentanyl deaths in the US?</p>	<p><u>Nicola Singleton, D. Ballotta, C. Costa Storti, E. Quigley & L. Vandam</u></p> <p>“Help! I have to evaluate our drug strategy” – the EMCDDA approach to promoting an evaluation culture in drug policy development in Europe</p>	<p><u>Laurent Gaissad, T. Madesclaire & M. Milhet</u></p> <p>Combining strategies: echoes from the APACHES chemsex study in France</p>	<p><u>Chelsea Cox</u></p> <p>One stream or two stream? Legal and policy considerations for maintaining a separate medical cannabis access stream in Canada</p>
	<p><u>Eric Gutierrez</u></p> <p>The paradox of illicit economies</p>		<p><u>Davide Fortin & M. Pardal</u></p> <p>In between recreational and medical cannabis supply models: is the Cannabis Social Club a potential buffer against market distortions?</p>	<p><u>Roberto Abadie</u></p> <p>Poverty, homelessness and barriers to access and retention in opioid agonist therapy for people who inject drugs</p>	<p><u>Mark Monaghan, E. Wincup & I. Hamilton</u></p> <p>Scandalous decisions: Understanding UK medicinal cannabis policy</p>
5 PM to 6 PM					

	ISSDP General Assembly				
7 PM to 9 PM	Reception				
Day 2: Thursday, May 23rd					
8:30 AM to 9:00 AM	Registration				
9 AM to 10:00 AM	Second plenary session: “Collaborating with peers in alcohol and other drug (AOD) research” Presentation by Jo Neale, professor of addictology at King’s College, in conversation with Jean-Maxence Granier of ASUD (the French drug users’ association) Chair: Marie Jauffret-Roustide				
10:00 AM to 11:30 AM	Advances in decriminalization efforts: theory and practice	Drug-related deaths as a public health problem: knowing, testing, responding	Measuring and preventing overdoses: individuals and community involvement	Results and lessons learned after five years of cannabis regulation in Uruguay	Drug Policies in African countries (Satellite Session organized by the Open Society Foundation)
Room	Auditorium	R2-01	R1-13	R1-14	R1-15
Chair	Willy Pedersen	Alex Stevens	Alissa Greer	Sebastian Aguiar	Fabrice Olivet
	<u>Pekka Hakkarainen</u> Decriminalization debate in Finland	<u>Basak Tas</u> Heroin overdose: Improving understanding through laboratory investigation	<u>Amanda Roxburgh, W. Hall, & L. Degenhardt</u> Correlates of opioid overdose deaths: do they differ between opioids?	<u>Marcos Baudean</u> Five years of cannabis regulation in Uruguay: what are the changes in health, security and justice? What can we learn from the Uruguayan experience of regulation?	<u>James Ndimbii</u> Harm reduction and peer-centered solutions in Kenya

	<p><u>Jonas von Hoffmann</u></p> <p>Cutting through the celeste haze: An assessment of the determinants of drug policy reform in Uruguay</p>	<p><u>Fay Dennis</u></p> <p>Accounting for overdose among older people who use heroin in the UK: A challenge to the ageing cohort theorem</p>	<p><u>Karla D. Wagner</u>, R. Harding, E. Copulsky, S. Verdugo, R. Kelley, B. Labus, J. Bowles, M.L. Mittal & P.J. Davidson</p> <p>Interventions triggered by calling 911 to seek emergency medical assistance for overdose in the US: Centering the perspectives of people who use drugs</p>	<p><u>Mauricio Coitiño</u></p> <p>Marijuana on the media in the era of regulation in Uruguay: 2013-2017</p>	<p><u>Albert Gautier Ndione</u></p> <p>Drug use, discrimination and difficulties in organizing drug users</p>
	<p><u>Caitlin Hughes</u>, A. Stevens, S. Hulme & R. Cassidy</p> <p>Models for the decriminalisation, depenalisation and diversion of illicit drug possession: An international realist review</p>	<p><u>Andrew McAuley</u></p> <p>What difference does it make? Assessing the impact of take-home naloxone scale up internationally</p>	<p><u>Penelope Hill</u>, P. Agius, M. Stoove, M. Hickman, L. Maher & P. Dietze</p> <p>Recent non-fatal opioid overdose: The effects of health service utilisation, alcohol and other drug use and demographic factors among people who inject drugs in Melbourne, Australia</p>	<p><u>Clara Musto</u></p> <p>In the backyard: Cannabis self-cultivation in Uruguay, 2014-2018</p>	<p><u>Moustapha Mbodj</u></p> <p>The role of Francophonie in the creation of a project for self-support groups in Senegal and in Africa (RAFASUD vs AFRICAPUD)</p>
	<p><u>Larissa J. Maier</u>, J. A. Ferris, M. J. Barratt & A. R. Winstock</p> <p>THC-infused – Analysis of edible and other cannabis use considering policy contexts in 14 countries</p>	<p><u>Zoe Carre</u></p> <p>Monitoring the availability and accessibility of take-home naloxone across England in 2017/18</p>		<p><u>Lorena Repetto</u></p> <p>The impact of marijuana sale at pharmacies on crime. A natural experiment</p>	<p><u>Samuel Roberts</u></p> <p>White and black harm reduction movement</p>
11:30 AM to 11:45 AM	Break				
11:45 AM to 1:15 PM	Cannabis legal and illegal market studies	Impact of cannabis policing on consumption and	The policing of international drug policies in Mexico	Drug policy as scapegoating: Explanations and effects	Race in the U.S. Opioid crisis (Satellite Session organized by the Drug

		communities			Policy Alliance
Room	Auditorium	R2-01	R1-13	R1-14	R1-15
Chair	Neil Boyd	Henri Bergeron	Alejandro Madrazo Lajous	Alex Stevens	Jules Netherland
	<u>Eliana Álvarez</u> Marijuana risk perception and consumption levels: a natural experiment with the pharmacies sales mechanism in Uruguay	<u>Charlie Lloyd</u> Lacking purpose: the policing of cannabis possession in the North of England	<u>Claire Moon</u> Delusions and lies: death denial in Mexico's war on drugs	<u>David Brewster</u> Migattena Ponchu (the selfish drug addict?) Culturing responses to drug use in Japan	<u>Samuel Roberts</u> Race, national belonging and the framing of drug scares
	<u>Rosalie Pacula</u> The development of new measures of cannabis market exposure: A case study in Colorado	<u>Marvin Krank</u> , T. Sanchez, M. Pilin & J. Robinson Changing how youth think about cannabis: The impact of legalization in Canada on under-aged youth	<u>Javier Trevino-Rangel</u> Torture manual: the social control of illicit drugs in Mexico	<u>Jack Spicer</u> Between gang talk and prohibition: Scapegoating and the transfer of blame for County Lines	<u>Helena Hansen</u> White racial marketing as driver of opioids in the US
	<u>Aaren Ivers & N. Boyd</u> Canada's mail order marijuana (MOM) market: Illicit online cannabis sales and the implications of legalization	<u>Ivana Obradovic</u> A comparative perspective on the emerging cannabis regulatory frameworks: first outcomes and unintended consequences (Uruguay, USA and Canada)	A. Madrazo Lajous, <u>Rebeca Calzada Olvera & J. J. Romero Vadillo</u> The "War on Drugs": Analysis of battles involving Public forces, 2006-2011	<u>Emma Wincup</u> Vindictive times: scapegoating destitute drug users	<u>Pedro Mateu-Gelabert</u> Opioid epidemic in the US: newfound sympathy for opioid users along with traditional punitive criminal justice
	<u>Adam Orens & M. Light</u> Colorado market evolution – 5 years in	<u>Renaud Colson</u> Challenging cannabis prohibition with doctrinal writing	<u>Nidia Andrea Olvera Hernández</u> The origins of prohibition and drug policy in México: Lessons from the past	<u>Shaun Shelly</u>	

1:15 PM to 2:30 PM	Lunch				
2:30 PM to 4 PM	The impact of decriminalization and legalization on issues of crime, race, and user perception	Not-for-profit models for regulated cannabis markets	Harm reduction as prevention: naloxone and digital monitoring	Alcohol, tobacco and other drug policies	Peer and other stakeholders' involvement in participatory research on harm reduction programs
Room	Auditorium	R2-01	R1-13	R1-14	R1-15
Chair	Caitlin Hughes	Simon Lenton	Ivana Obradovic	Esben Houborg	Marie Jauffret-Roustide
	<u>Edwin Grimsley</u> Decriminalization, racialization and criminalization: Toward a theory of legalization policy for marijuana in New York City	<u>Tom Decorte, M. Pardal, O. Parés, M. Bone & J. Johansson</u> Mapping cannabis social clubs in Europe	<u>Róbert Csák, J. Arsenijević, P. Sárosi, I. Molnar & B. Arsenijević</u> Different environments, different risk behaviors: Consequences of decreased coverage of needle exchange programs in Budapest and Belgrade	<u>Thomas Kattau</u> Towards a new balanced approach: Ensuring public health and safety while guaranteeing individual rights	<u>Jean-Michel Delile & Jean-Hugues Morales, K. Bertrand, J. Flores-Aranda, J. Tremblay, K. Alunni-Menichini, A. C. Villela Guilhon, S. Brochu, E. Roy, J. D. Mahoney & T. Haig</u> The involvement of workplace and health care stakeholders in the development and implementation of TAPAJ, a comprehensive approach to harm reduction based on low-threshold work in Quebec and France
	<u>Rosario Queirolo, J. Bowers, E. Alvarez & L. Repetto</u> The impact of marijuana sale at pharmacies on users' stigmatization, law approval, insecurity perceptions and	<u>Marta Rychert</u> Could New Zealand's community trust model for alcohol be applied to regulate legal cannabis?	<u>Vivienne Moxham-Hall, C. Hughes & A. Ritter</u> Lost in translation? The effect of good samaritan and naloxone opioid overdose prevention laws "on the	<u>Claudia Costa Storti, B. Casal & D. Morgan</u> How much does drug and alcohol hospital treatment cost in Europe?	<u>Michel Perreault & Guillaume Tremblay, A-C. Artunduaga, C. Perron, C. Marshall & D. Milton</u> Perceived impact of

	crime victimization		books” on opioid overdose mortality rates in the United States		participation in a peer-training overdose prevention program
	<u>Catalina Perez Correa & A. Ruiz</u> In the name of public health: marijuana eradication and use of paraquat in Mexico	<u>Mafalda Pardal</u> Uruguayan cannabis social clubs: From activism to dispensaries?	<u>Magali Martinez, M. Pazitny & V. Belackova</u> Fentanyl and opioids NPS: Catching low digital signals for preventing public health crisis	<u>Claire Wilkinson</u> From “public need” to “public interest”: Comparative analysis of liquor licensing tests in Australian jurisdictions	<u>Karine Bertrand & Shane Knight</u> , J. Flores-Aranda, J. Tremblay, K. Alunni-Menichini, A. C. Villela Guilhon, S. Brochu, É. Roy, J. D. Mahoney & T. Haig Young people’s perspectives on a harm reduction program based on low-threshold work: Insights for social and health policy
	<u>Anne Line Bretteville-Jensen & L. Gjersing</u> To what extent will the drug-crime nexus remain after drug laws liberalization? An examination of criminal charges among patients in treatment for cannabis use disorders and controls under varied drug policy regimes	<u>Catalina Pérez Correa</u> A proposal for marijuana legislation in Mexico	<u>Suzanna Nielsen & A. Olsen</u> Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply	<u>Virginia Berridge</u> E-cigarettes and policy responses: evidence, history and harm reduction	
4 PM to 4:30 PM	Break				
4:30 PM to 6 PM	Evaluation of cannabis consumption, legalization and an innovative approach	Epidemiological and critical perspectives on the elimination of hepatitis C virus in people who inject drugs (INSHU Session)	Community responses and outreach for prevention and harm reduction	Global issues of drug policy and theoretical analytical models	Latest evidence on illicit drug economies in developing countries

Room	Auditorium	R2-01	R1-13	R1-14	R1-15
Chair	Peter Reuter	Sarah Larney	Alison Ritter	Nicola Singleton	Daniel Brombacher
	T. Moss, <u>Devon De Silva</u> Capital Card® Evaluation	<u>Sarah Larney</u> Global epidemiology of hepatitis C in people who inject drugs	<u>Olanrewaju Onigbogi</u> Willingness to participate in peer engagement efforts in drug policy among out-of-school youths in Lagos, Nigeria	<u>Carla Rossi</u> Epidemiological models of heroin epidemics and social outcomes to evaluate illicit drug policy in various countries	A. Me & <u>Anja Korenblik</u> Evidence for policy-making: the number of households involved in illicit drug crop cultivation and the number of beneficiaries of alternative development
	<u>Pierre-Yves Geoffard</u> Economic and fiscal impacts of cannabis legalisation in France	<u>Matt Hickman</u> Epidemiology and public health surveillance of HCV prevention in people who inject drugs	<u>Mary Ellen Harrod, N. Lintzeris, L. Monds, M. Bravo, M. Joyce, P. Read & S Nielsen</u> The NSW ORTHN Project: Implementing THN programs across AoD, NSP and outreach services	<u>Artur Malczewski, K. Abel-Ollo, L. Isajeva & L. Jurgelaitienė</u> Opioid-related problems in Baltic States and Poland: Has the turning point come?	<u>Juan Carlos Garzón Vergara</u> The weakest link: A socio-demographic characterization of small coca growers in Putumayo, Colombia
	<u>Megan Weier</u> Exploring different “evidences” in Australian medicinal cannabis policy	<u>Kari Lancaster</u> Performing hepatitis C elimination: A critical examination of productive capacity and constitutive effects of target-setting	<u>Michelle Van Impe</u> Who are we and what do we want? Critical participatory action research with people who use illegal drugs.	<u>Alexandra Scott</u> Distribution of power among the global political actors along the Northern trafficking route.	<u>Deborah Alimi</u> Illicit drugs economies as a “develoPMent issue”? Survey of drug-related constraints on donors’ intervention and development cooperation in fragile contexts
	<u>Jasmina Burdzovic Andreas, A. L. Bretteville-Jensen & H. Gjerde</u> Who lies about having used drugs?: Under-reporting of cannabis, cocaine, and ecstasy use in a sample of nightlife	<u>Tim Rhodes</u> Evidence-making elimination: Modelling, targets and the end of hepatitis C	<u>Alissa Greer</u> Engaging the affected community in drug policymaking: Examining systems of inequity in peer-based work among people who use drugs	<u>Lena Eriksson</u> The ideological trade-off as the scientific epistemic culture meets the political: The case of needle exchange policy in Sweden	<u>Salwa Massad</u> Estimating the extent of illicit drug use in Palestine: A cross-sectional study

	patrons in Norway				
7.30 PM to 11 PM	Conference dinner				

Day 3: Friday, May 24 th					
8:30 AM to 9 AM	Registration				
8:30 AM to 10:00 AM	Analyses of global cannabis sales and regulation models	Evolutions in policing among drug users and marginalized communities	Applied innovations in analysis, interpretation and modeling	International advances in harm reduction innovations	Impact of drug policies on norms, communities, and social groups
Room	Auditorium	R2-01	R1-13	R1-14	R1-15
Chair	Tom Decorte	Aili Malm	Rosalie Pacula	Sam Shirley-Beavan	Aileen O’Gorman
	<u>Toby Seddon & W. Floodgate</u> Cannabis law reform: Global review and critical prospectus	<u>Tobias Kammersgaard</u> From drug law enforcement to protection: Policing marginalized drug users after decriminalization	Z. Walsh, <u>Stacey Squires & S. Daniels</u> The Index of Cannabis Equivalence (ICE); A new way to look at cannabis	<u>Jennifer Hasselgard-Rowe</u> Cambodia’s legal and judicial structure: a serious impediment to reforming the country’s drug policies and	M. Germes, <u>Luise Klaus</u> Drug policies within urban spaces. Emo-mapping as an innovative qualitative cartography method

			dosage	practices	
	<p><u>Neil Boyd</u></p> <p>Canada's legalization of cannabis: A patchwork quilt in progress?</p>	<p><u>Michael White</u></p> <p>Exploring police officers' use of de-escalation in encounters with intoxicated citizens</p>	<p>E. Auriol, <u>Alice Mesnard</u> & T. Perrault</p> <p>Defeating crime? An economic analysis of cannabis legalization policies</p>	<p><u>Cameron Wild</u>, J. Koziel, J. Anderson-Baron, M. Asbridge, L. Belle-Isle, C. Dell, R. Elliott, A. Hathaway, D. MacPherson, K. McBride, B. Pauly, C. Strike, K. Tupper & E. Hyshka</p> <p>Prevalence and correlates of support for harm reduction in a population survey of Canadian adults</p>	<p><u>Simon Flacks</u></p> <p>School drugs policies: The politics of punishment</p>
	<p><u>Robin Room</u></p> <p>Government monopoly as an instrument for public health and welfare: Lessons for cannabis from experience with alcohol and other public-interest monopolies</p>	<p><u>Dina Perrone</u>, A. Malm, & E. Magana</p> <p>A process evaluation of Law Enforcement Assisted Diversion (LEAD) implementation in California</p>	<p><u>Emmanuelle Godeau</u>, V. Ehlinger & S. Spilka</p> <p>EnCLASS: An innovative survey to contribute to drug policies analysis among school-students in France</p>	<p><u>Alison Ritter</u></p> <p>Making drug policy in summer – Drug checking as providing more heat than light</p>	<p><u>Gideon Lasco</u> & I. Feria</p> <p>The impacts of drug testing in Philippine schools</p>
	<p><u>Patrick Oglesby</u></p> <p>Cannabis regulation models – Follow the revenue</p>	<p><u>Kristelle Alunni-Menichini</u>, K. Bertrand, E. Roy & A. Brousselle</p> <p>Current emergency response to homeless people who use psychoactive substances in Montreal: Results from a systemic and multi-stakeholder perspective</p>	<p>A. Abraham, <u>Grace Adams</u>, D. Bradford, A. Bradford & S. Harris</p> <p>Throwing good money after bad docs: The relationship between physician gifts and U.S. Department of Health and Human Services exclusion</p>	<p><u>Cécilia Comelli</u> & E. Fahlke</p> <p>Night-time drug policies: How stakeholders make adjustments for implementing harm reduction strategies within festive settings in France</p>	<p><u>Tatiana A. Sanchez</u>, Z. Walsh, M. Krank, S.A. Daniels & M. St. Pierre</p> <p>The impact of cannabis legalization on the social norms of cannabis use in youth</p>
10:00 AM to 10:30 AM	Break				

10:30 AM to 12:00 PM	Global comparative policy analyses	Issues of stigma in recovery and maintenance	Cryptomarkets, amphetamines and LSD	Gender issues, narratives, and violence	
Room	Auditorium	R2-01	R1-13	R1-14	R1-15
Chair	Atul Ambekar	Charlie Lloyd	Michala Kowalski	Kari Lancaster	
	<u>Alejandra Cervantes Nieto</u> The fight against drug trafficking in East Asia: A comparison of government policies designed to combat drug trafficking in China, Japan and the Philippines.	<u>Nguyen Thu Trang, M. Jauffret-Roustide, G. Le Minh & L. Visier</u> How to be self-reliant within a context of stigma? The dilemma of injection drug users in Vietnam	<u>Bryan Monk & R. Frank</u> The evolution of cryptomarket vendors' transaction networks	<u>Polly Radcliffe, D. Gadd, B. Love, J. Henderson, D. Lewis-Jones, A. Johnson, L. Gilchrist & G. Gilchrist</u> The contribution of substance use in intimate partner violence. Misuses of evidence in the England and Wales Domestic Abuse Bill 2019	
	<u>A. Zainal, Anggara & Maidina Rahmawati</u> Analyzing fair trial aspect of death penalty for drug cases in Indonesia: Policy and implementation: Special cases on women	<u>Lore Bellaert, F. Vander Laenen, C. Colman, T. F. Martinelli & W. Vanderplasschen</u> Recovery discourse in drug policies versus actual practice in Belgium and the Netherlands	<u>Sam Shirley-Beavan & K. Stone</u> Amphetamine-type stimulant use: Global trends in the harm reduction response	<u>M. Plotko, A. Kontautaitė, D. Matyushina, M. Golichenko, M. Kalvet, & E. Antonova</u> Study of human rights violations faced by women who use drugs in Estonia	
	<u>Emile Dirks</u> China's war on drugs: Quantitative analysis of thirty years of policy successes and failures	<u>J. Aldridge, M. Barratt, Gary Potter & A. Ross</u> "Coming out": Stigma, reflexivity and the drug researcher's drug use	<u>P. Haave & Willy Pedersen</u> LSD-based psychotherapy in Norway in the 1960s	<u>Rebecca Askew</u> Reflecting upon gendered narratives in discussions about drug policy and the law	
	<u>Marie Nougier</u> Taking stock of the past	<u>Karen Black & A. O'Gorman</u> Drug policy dissonance:	<u>Thomas Friis Sogaard</u> The ubernisation of drug	<u>Rose Andre Faye, A. Desclaux, K. Sow & G. Laborde-Balen</u>	

	decade of UN drug control: Drawing lessons for the future	Alternative voices of recovery in an abstinence-oriented policy environment.	markets: User motives for sourcing drugs from “ring and bring” delivery services	Barriers to access to Dakar addiction treatment center (CEPIAD): Differences in perceptions between male and female injectable drugs users	
12 PM to 12:45 PM	The Franz Trautmann Memorial Lecture By Angela Me, Chief Research and Trend Analysis Branch-United Nations Office on Drugs and Crime (UNODC) Drugs and Development Chair: Nicola Singleton				
12:45 PM to 1 PM	Concluding remarks				
2.00 PM to 5PM	Workshop 1: Civil Society Involvement in Drug Policy”- what can we learn from each other from a research, policy and civil society perspective (Eberhard Schatz) – R1-14				
2.00 PM to 5PM	Workshop 2: Improving the creation and use of legal data in comparative drug and alcohol policy research (Scott Burris, Caitlin Hughes & Rosalie Liccardo Pacula) – R1-15				
2.30PM to 6PM	Press conference: Symposium sur la recherche scientifique et l’action publique en matière de drogues (événement de presse en français organisé par Médecins du Monde, la Fédération Addiction, et le programme D3S (Sciences Sociales, Drogues et Société) de l’EHESS, Auditorium				